Loading clinical trials...
Loading clinical trials...
A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Conditions
Interventions
MGCD516
Locations
43
United States
University of Alabama
Birmingham, Alabama, United States
University of California, San Diego
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Sarcoma Oncology Research Center
Santa Monica, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Start Date
August 1, 2014
Primary Completion Date
April 27, 2022
Completion Date
April 27, 2022
Last Updated
March 6, 2023
NCT04657068
NCT04900818
NCT05004116
NCT06440005
NCT07246954
NCT06242470
Lead Sponsor
Mirati Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions